9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, which is mainly due to late diagnosis and profound resistance to treatment. The latter is to a large extent attributed to the tumor stroma that is exceedingly prominent in PDAC and engages in complex interactions with the cancer cells. Hence, relevant preclinical models of PDAC should also include the tumor stroma. We herein describe the establishment and functional validation of an ex vivo organotypic culture of human PDAC that is based on precision-cut tissue slices from surgical specimens and reproducibly recapitulates the complex cellular and acellular composition of PDAC, including its microenvironment. The cancer cells, tumor microenvironment and interspersed remnants of nonneoplastic pancreas contained in these 350 µm thick slices maintained their structural integrity, phenotypic characteristics and functional activity when in culture for at least 4 days. In particular, tumor cell proliferation persisted and the grade of differentiation and morphological phenotype remained unaltered. Cultured tissue slices were metabolically active and responsive to rapamycin, an mTOR inhibitor. This culture system is to date the closest surrogate to the parent carcinoma and harbors great potential as a drug sensitivity testing system for the personalized treatment of PDAC.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma

          (2017)
          We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. Deep whole-exome sequencing revealed recurrent somatic mutations in KRAS, TP53, CDKN2A, SMAD4, RNF43, ARID1A, TGFβR2, GNAS, RREB1, and PBRM1. KRAS wild-type tumors harbored alterations in other oncogenic drivers, including GNAS, BRAF, CTNNB1, and additional RAS pathway genes. A subset of tumors harbored multiple KRAS mutations, with some showing evidence of biallelic mutations. Protein profiling identified a favorable prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway scores. Associations of non-coding RNAs with tumor-specific mRNA subtypes were also identified. Our integrated multi-platform analysis reveals a complex molecular landscape of PDAC and provides a roadmap for precision medicine.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Capturing complex 3D tissue physiology in vitro.

            The emergence of tissue engineering raises new possibilities for the study of complex physiological and pathophysiological processes in vitro. Many tools are now available to create 3D tissue models in vitro, but the blueprints for what to make have been slower to arrive. We discuss here some of the 'design principles' for recreating the interwoven set of biochemical and mechanical cues in the cellular microenvironment, and the methods for implementing them. We emphasize applications that involve epithelial tissues for which 3D models could explain mechanisms of disease or aid in drug development.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Stromal biology and therapy in pancreatic cancer: a changing paradigm.

              Pancreatic ductal adenocarcinoma (PDA) exhibits one of the poorest prognosis of all solid tumours and poses an unsolved problem in cancer medicine. Despite the recent success of two combination chemotherapies for palliative patients, the modest survival benefits are often traded against significant side effects and a compromised quality of life. Although the molecular events underlying the initiation and progression of PDA have been intensively studied and are increasingly understood, the reasons for the poor therapeutic response are hardly apprehended. One leading hypothesis over the last few years has been that the pronounced tumour microenvironment in PDA not only promotes carcinogenesis and tumour progression but also mediates therapeutic resistance. To this end, targeting of various stromal components and pathways was considered a promising strategy to biochemically and biophysically enhance therapeutic response. However, none of the efforts have yet led to efficacious and approved therapies in patients. Additionally, recent data have shown that tumour-associated fibroblasts may restrain rather than promote tumour growth, reinforcing the need to critically revisit the complexity and complicity of the tumour-stroma with translational implications for future therapy and clinical trial design.
                Bookmark

                Author and article information

                Contributors
                c.s.verbeke@medisin.uio.no
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                14 February 2019
                14 February 2019
                2019
                : 9
                : 2133
                Affiliations
                [1 ]ISNI 0000 0000 9241 5705, GRID grid.24381.3c, Department of Laboratory Medicine, Division of Pathology F46, Karolinska Institutet, , Karolinska University Hospital Huddinge, ; SE-141 86, Stockholm, Sweden
                [2 ]ISNI 0000 0004 1937 0626, GRID grid.4714.6, Department of Clinical Intervention and Technology (CLINTEC), Center for Digestive Diseases, , Karolinska University Hospital and Division of Surgery, Karolinska Institutet, ; Stockholm, 14186 Sweden
                [3 ]ISNI 0000 0000 9241 5705, GRID grid.24381.3c, Department of Clinical Pathology/Cytology, , Karolinska University Hospital, ; Stockholm, SE-141 86 Sweden
                [4 ]ISNI 0000 0001 0942 9821, GRID grid.11804.3c, Tumour Biology Laboratory, 1st Department of Pathology and Experimental Cancer Research, , Semmelweis University, ; Budapest, 1085 Ulloi ut 26. Hungary
                [5 ]ISNI 0000 0004 1936 8921, GRID grid.5510.1, Institute of Clinical Medicine, , University of Oslo, ; Postbox 1171 Blindern, Oslo, 0318 Norway
                [6 ]ISNI 0000 0004 0389 8485, GRID grid.55325.34, Department of Pathology, , Oslo University Hospital, Rikshospitalet, ; Postbox 4956 Nydalen, Oslo, 0424 Norway
                Author information
                http://orcid.org/0000-0003-1660-9438
                http://orcid.org/0000-0001-6863-5959
                http://orcid.org/0000-0002-7647-198X
                Article
                38603
                10.1038/s41598-019-38603-w
                6376017
                30765891
                39f08168-8a1d-4f3b-b785-26a390d5a4a7
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 25 June 2018
                : 3 January 2019
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                Uncategorized

                Comments

                Comment on this article